The company’s first patents were written by Dr. Daniel Kligler, who worked in close cooperation with Biosense’s team of inventors, led by Asaf Gov-Ari. In its first year of operation, the pioneering startup company had already filed approximately twenty patent applications in the U.S. and Israel that were written by Mr. Kligler. This number would increase each year, as new patents were added at a consistent pace.

“The goal of the company’s first patent applications was first and foremost to protect their groundbreaking technology, namely the procedure of ablation via advanced catheters,” says Kligler. “It sent a strong message to the other players in the sector – that this revolutionary field is protected for a period of twenty years (the lifespan of the patent), wherever the patent has been filed.”

With their technology protected by such strong patents, Biosense became an attractive acquisition target. Johnson & Johnson jumped at the opportunity of acquiring them, and their attractive patent portfolio along with it. Typically, a conglomerate like Johnson & Johnson will then bring on their own patent attorneys to handle the new unit of their business. However, this was not the case with Biosense.

The patents unit of Johnson & Johnson was so thoroughly impressed with the company’s comprehensive patent protection, that they decided to continue working with Kligler & Associates to register patents for Biosense – now its subsidiary – both in the U.S. and in Israel. “We chose to continue working with Kligler & Associates also in the framework of Johnson & Johnson because of the proven success of registering patents with a deterring effect, because of the professional staff that provides us with a swift and thorough response up to international standards, and above all – thanks to the firm’s deep understanding of our technology,” says Gov-Ari, today the manager of Biosense’s Advanced R&D team within Johnson & Johnson.

In the twenty year span since then, Daniel Kligler and his team are responsible for the filing of more than 400 patent applications in the U.S. for Biosense. All patents are filed according to a specific methodology that has led to optimal patent protection. “Once a month we meet with the company’s engineers to identify the most innovative inventions, which will protect Biosense and build upon its commercial success,” says Kligler. The working process includes meetings between the patent writers, all of whom have an appropriate engineering background, and the company’s engineering development team, to discuss the essence of the inventions’ technologies, and to move forward from there to writing the patent application and preparing to file it in the U.S. Patent Office. Based on the applications filed in the U.S., Biosense files applications in Israel.